CoChat

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Hart, Lori S., Rader, JulieAnn, Raman, Pichai, Batra, Vandana, Russell, Mike R., Tsang, Matthew, Gagliardi, Maria, Chen, Lucy, Martinez, Daniel, Li, Yimei, Wood, Andrew, Kim, Sunkyu, Parasuraman, Sudha, Delach, Scott, Cole, Kristina A., Krupa, Shiva, Boehm, Markus, Peters, Malte, Caponigro, Giordano, Maris, John M. · 2017 · Clinical Cancer Research
Cited by 82

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Purpose: Neuroblastoma is treated with aggressive multimodal therapy, yet more than 50% of patients experience relapse. We recently showed that relapsed neuroblastomas frequently harbor mutations leading to hyperactivated ERK signaling and sensitivity to MEK inhibition therapy. Here we sought to define a synergistic therapeutic partner to potentiate MEK inhibition. Experimental Design: We first surveyed 22 genetically annotated human neuroblastoma-derived cell lines (from 20 unique patients) for sensitivity to the MEK inhibitor binimetinib. After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell-cycle analysis, Ki67 immunostaining, time-lapse microscopy, and xenograft studies. Results: Sensitivity to binimetinib and ribociclib was inversely related (r = −0.58, P = 0.009). MYCN amplification status and expression were associated with ribociclib sensitivity and binimetinib resistance, whereas increased MAPK signaling was the main determinant of binimetinib sensitivity and ribociclib resistance. Treatment with both compounds resulted in synergistic or additive cellular growth inhibition in all lines tested and significant inhibition of tumor growth in three of four xenograft models of neuroblastoma. The augmented growth inhibition was attributed to diminished cell-cycle progression that was reversible upon removal of drugs. Conclusions: Here we demonstrate that combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models. These data support testing this combination therapy in relapsed high-risk neuroblastoma patients, with focus on cases with hyperactivated RAS–MAPK signaling. Clin Cancer Res; 23(7); 1785–96. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1131

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 82

Metadata

Authors
Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M., Chen, L., Martinez, D., Li, Y., Wood, A., Kim, S., Parasuraman, S., Delach, S., Cole, K. A., Krupa, S., Boehm, M., Peters, M., Caponigro, G., & Maris, J. M.
Venue
Clinical Cancer Research
Published
2017-04-01
Volume
23
Issue
7
Pages
1785-1796
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2530482928
Cited by
82
References
8
FWCI
6.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1131
The paper
Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M., Chen, L., Martinez, D., Li, Y., Wood, A., Kim, S., Parasuraman, S., Delach, S., Cole, K. A., Krupa, S., Boehm, M., Peters, M., Caponigro, G., & Maris, J. M. (2017). Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.